Suppr超能文献

基于体表面积的心律失常患儿静脉注射索他洛尔的剂量

Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia.

作者信息

Li Xiaomei, Zhang Yan, Liu Haiju, Jiang He, Ge Haiyan, Zhang Yi

机构信息

Department of Pediatric Cardiology, Heart Center, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua University, Beijing, 100016, People's Republic of China.

出版信息

Pediatr Cardiol. 2017 Oct;38(7):1450-1455. doi: 10.1007/s00246-017-1683-9. Epub 2017 Jul 28.

Abstract

In a recently published study, we evaluated the efficacy and safety of intravenous sotalol in pediatric patients with incessant tachyarrhythmias and we have found that intravenous sotalol is effective and safe. Our dosing regimen was based on the body weight of the patients. In the US, the recommendation for intravenous sotalol dosing in pediatric patients is based on body surface area (BSA) while taking into consideration the patients' age. The purpose of this paper is to show the correspondence of a body weight-based dosing regimen when expressed for BSA as mg/m. We evaluated the similarity of a body weight-based dose to that calculated based on BSA using the US labeling recommendations. Of the 83 patients, 5 were newborns (age: 0-30 days), 39 infants and toddlers (age: 1-24 month), 26 young children (age: >2-6 years), 11 older children (age: 6-12 years), and 2 adolescents (age: 14 years). Each received a loading dose of 1 mg/kg intravenous sotalol administered over 10 min followed by a maintenance dose of 4.5 mg/kg/day. There was a close correlation between the sotalol loading doses calculated based on body weight and BSA across the entire age range (r = 0.977, p < 0.001). In most of the age groups, the body weight-based loading doses were lower or equal to the BSA-based doses. Only in the adolescents were the body weight-based doses higher. The maintenance doses given in our study were significantly higher than the BSA-based dose in newborns: 75 ± 6 versus 53 ± 8 mg/m, p < 0.05; infants/toddlers: 88 ± 14 versus 77 ± 7 mg/m, p < 0.001; younger children: 113 ± 12 versus 85 mg/m, p < 0.001; older children: 123 ± 16 versus 85 mg/m, p < 0.01; and adolescents 157 ± 30 versus 85.5 mg/m. Despite the rapid administration of the loading dose and the increased maintenance doses, our body weight-based dosing regimen was safe. Only one newborn had significant adverse event (AV block) that resolved spontaneously after discontinuation of the infusion.

摘要

在最近发表的一项研究中,我们评估了静脉注射索他洛尔在患有持续性快速心律失常的儿科患者中的疗效和安全性,并且我们发现静脉注射索他洛尔是有效且安全的。我们的给药方案基于患者的体重。在美国,儿科患者静脉注射索他洛尔的给药建议是基于体表面积(BSA),同时考虑患者的年龄。本文的目的是展示以体重为基础的给药方案在以毫克每平方米(mg/m²)表示为BSA时的对应关系。我们使用美国药品标签建议评估了基于体重的剂量与基于BSA计算的剂量的相似性。在这83名患者中,5名是新生儿(年龄:0 - 30天),39名婴幼儿(年龄:1 - 24个月),26名幼儿(年龄:>2 - 6岁),11名大龄儿童(年龄:6 - 12岁),以及2名青少年(年龄:14岁)。每人接受1毫克/千克的静脉注射索他洛尔负荷剂量,在10分钟内给药,随后是4.5毫克/千克/天的维持剂量。在整个年龄范围内,基于体重计算的索他洛尔负荷剂量与基于BSA的剂量之间存在密切相关性(r = 0.977,p < 0.001)。在大多数年龄组中,基于体重的负荷剂量低于或等于基于BSA的剂量。仅在青少年中,基于体重的剂量较高。我们研究中给予的维持剂量在新生儿中显著高于基于BSA的剂量:75±6对比53±8毫克/平方米,p < 0.05;婴幼儿:88±14对比77±7毫克/平方米,p < 0.001;幼儿:113±12对比85毫克/平方米,p < 0.001;大龄儿童:123±16对比85毫克/平方米,p < 0.01;青少年157±30对比

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d490/5628187/c3818969a44a/246_2017_1683_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验